India’s Ranbaxy, Three Other Generics Named In Buy-Off Suit By U.S. FTC
This article was originally published in PharmAsia News
Ranbaxy Pharmaceuticals of India has been named among four companies Cephalon is alleged to have paid to delay marketing a generic version of the American company's Provigil (modafinil) narcolepsy drug. The suit was filed in the U.S. District Court in Washington for the Federal Trade Commission, which said Cephalon had acted to protect a drug worth $800 million in annual sales. Besides Ranbaxy, which did not comment on the suit, other drug makers accused of providing $200 million worth of inducements were Barr Pharmaceuticals, Mylan Pharmaceuticals and Teva Pharmaceutical Industries. (Click here for more - a subscription may be required )
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.